Analytical Data
-
Gene name
TCEA3
- Application
-
Alternative Names
TCEA3；TFIISH；Transcription elongation factor A Protein 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75764
-
Expression Region
1-348aa
-
AA Sequence
MGQEEELLRI AKKLEKMVAR KNTEGALDLL KKLHSCQMSI QLLQTTRIGV AVNGVRKHCS DKEVVSLAKV LIKNWKRLLD SPGPPKGEKG EEREKAKKKE KGLECSDWKP EAGLSPPRKK REDPKTRRDS VDSKSSASSS PKRPSVERSN SSKSKAESPK TPSSPLTPTF ASSMCLLAPC YLTGDSVRDK CVEMLSAALK ADDDYKDYGV NCDKMASEIE DHIYQELKST DMKYRNRVRS RISNLKDPRN PGLRRNVLSG AISAGLIAKM TAEEMASDEL RELRNAMTQE AIREHQMAKT GGTTTDLFQC SKCKKKNCTY NQVQTRSADE PMTTFVLCNE CGNRWKFC
-
Molecular Weight
38.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TCEA3, or Transcription Elongation Factor A (SII), has garnered significant attention in recent years due to its crucial role in the regulation of gene expression and RNA processing. As a member of the transcription elongation factor family, TCEA3 is involved in the recruitment of RNA polymerase II and the elongation of nascent RNA transcripts, thereby influencing cellular responses to various stimuli and developmental cues. Dysregulation of TCEA3 has been implicated in several diseases, including cancer, where it may contribute to altered gene expression profiles and tumor progression. The study of TCEA3 is further propelled by its potential as a therapeutic target; understanding its structure and function can lead to the development of novel strategies for manipulating transcriptional regulation in pathological conditions. Recent advancements in recombinant protein technologies have enabled researchers to produce TCEA3 in vitro, facilitating detailed investigations into its biochemical properties and interactions with other cellular components. By elucidating the molecular mechanisms underlying TCEA3's functions, scientists aim to uncover its role in normal physiology and disease etiology, ultimately paving the way for innovative approaches in disease treatment and prevention. This growing body of research highlights the significance of TCEA3 as both a fundamental biological entity and a promising target for therapeutic intervention.
